Investigator

Dan Peer

Tel Aviv University, Office Of The Vice President For Research & Develo

Research Interests

DPDan Peer
Papers(3)
Therapeutic gene sile…An ovarian spheroid b…Therapeutic Gene Sile…
Collaborators(5)
David SprinzakGonna Somu NaiduMeir GoldsmithRonen Zaidel-BarSushmita Chatterjee
Institutions(1)
Tel Aviv University

Papers

Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer

AbstractOvarian cancer is an aggressive tumor owing to its ability to metastasize from stage II onward. Herein, lipid nanoparticles (LNPs) that encapsulate combination of small interfering RNAs (siRNAs), polo‐like kinase‐1 (PLK1), and eukaryotic translation‐initiation factor 3c (eIF3c), to target different cellular pathways essential for ovarian cancer progression are generated. The LNPs are further modified with hyaluronan (tNPs) to target cluster of differentiation 44 (CD44) expressing cells. Interestingly, hyaluronan‐coated LNPs (tNPs) prolong functional activity and reduce growth kinetics of spheroids in in vitro assay as compared to uncoated LNPs (uNPs) due to ≈1500‐fold higher expression of CD44. Treatment of 2D and 3D cultured ovarian cancer cells with LNPs encapsulating both siRNAs result in 85% cell death and robust target gene silencing. In advanced orthotopic ovarian cancer model, intraperitoneal administration of LNPs demonstrates CD44 specific tumor targeting of tNPs compared to uNPs and robust gene silencing in tissues involved in ovarian cancer pathophysiology. At very low siRNA dose, enhanced overall survival of 60% for tNPs treated mice is observed compared to 10% and 20% for single siRNA‐, eIF3c‐tNP, and PLK1‐tNP treatment groups, respectively. Overall, LNPs represent promising platform in the treatment of advanced ovarian cancer by improving median‐ and overall‐survival.

121Works
3Papers
5Collaborators
NeoplasmsColitisDisease Models, AnimalCell Line, TumorOvarian NeoplasmsTumor Necrosis Factor-alphaBacterial InfectionsLung Neoplasms

Positions

2020–

Researcher

Tel Aviv University · Office Of The Vice President For Research & Develo

2008–

Researcher

Tel Aviv University · Department Of Cell Research And Immunology

2008–

Researcher

Tel Aviv University · Laboratory of Precision NanoMedicine

Education

2004

Ph.D.

Tel Aviv University

Keywords
drug deliveryMolecular MedicinesRNA Therapeutics and VaccinesLNPs
Links & IDs
0000-0001-8238-0673Peer Laboratory of NanoMedicine

Scopus: 13610740700

Researcher Id: A-1785-2011